MétaCan
Menu
← Back to cohort

Tumor molecular profiling to differentiate extreme responses to first-line platinum-based chemotherapy in suboptimally debulked serous ovarian cancer patients.

2018· article· en· W2891144912 on OpenAlexaff
Johanne I. Weberpals, Trevor J. Pugh, Glenwood D. Goss, Bernard Lo, Natalie Andrews Wright, Laurence Bernard, Dax Torti, Jonathon Torchia, Prisni Rath, Alberto J. León, Kayla Marsh, Darren Hodgson, Gemma N. Jones, Marc M. Duciaume, William Howat, Paola Marco‐Casanova, Martine P. Roudier, Doreen Whelan, Harmanjatinder S. Sekhon

Bibliographic record

VenueJournal of Clinical Oncology · 2018
Typearticle
Languageen
FieldMedicine
TopicOvarian cancer diagnosis and treatment
Canadian institutionsUniversity of OttawaInstitute of Cancer ResearchOntario Institute for Cancer ResearchOttawa HospitalPrincess Margaret Cancer CentreUniversity Health Network
Fundersnot available
KeywordsCarboplatinMedicineSerous fluidOncologyInternal medicineOvarian cancerDebulkingChemotherapyOlaparibExomeExome sequencingCancerCancer researchMutationCisplatinGeneBiologyGenetics

Abstract

fetched live from OpenAlex

5561 Background: Patients with advanced high grade serous ovarian cancer (SOC) who undergo a suboptimal debulking primary surgery typically have adverse clinical outcomes. However, a spectrum of sensitivity to first line platinum-based chemotherapy is observed but poorly understood. In this study, we perform molecular characterization of two groups of responders (extreme versus poor) to first line carboplatin/taxol chemotherapy in suboptimally debulked SOC patients. Methods: Suboptimally debulked SOC patients with advanced disease (stage III-IV) were grouped by response to first-line chemotherapy and clinicopathologic data collected. Extreme platinum-sensitive (PS) responders had a PFI (progression-free interval) > 12 months (mo) and platinum-resistant (PR) responders had a PFI < 6mo. Tissue specimens were used to interrogate the molecular features of both PS and PR cohorts using whole exome and transcriptome sequencing. Sequence alignment and variant calling were performed using GATK and annotation was performed using Variant Effect Predictor for assessment of non-synonymous tumor mutation burden (TMB) and discovery of novel mutational signatures to predict platinum response. Results: There were 39 patient samples analyzed from primary surgery (PS group = 20; PR group = 19). Median PFI for PS and PR patient cohorts was 30 mo and 3 mo (p < 0.001), respectively. In all tumors, in addition to BRCA and TP53 mutations, additional oncogenic mutations were noted in genes associated with PI3K/AKT/mTOR signaling and in epigenetic regulation. The PS samples were characterized by mutations in BRCA1/2 and the PR samples by mutations in MGA. Compared to tumors in the PR cohort, PS tumors had a significantly higher non-synonymous mutation rate using TMP analysis (p < 0.05) with a trend towards increased immune response. Additional bioinformatics analysis is ongoing and will include copy number variation analysis, immune inference using ESTIMATE and Gene Set Enrichment Analysis. Conclusions: Contracting a mutational signature is feasible from patient tumors at primary surgery and helps to elucidate extreme responses to platinum-based chemotherapy.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.001
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.001
Threshold uncertainty score0.003

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0000.001
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0010.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0010.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.108
GPT teacher head0.436
Teacher spread0.327 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations3
Published2018
Admission routes1
Has abstractyes

Explore more

Same venueJournal of Clinical Oncology→Same topicOvarian cancer diagnosis and treatment→French-language works237,207→